{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:15:40Z","timestamp":1790691340041,"version":"4.1.0"},"reference-count":132,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2018,12,24]],"date-time":"2018-12-24T00:00:00Z","timestamp":1545609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Cancer has a high incidence and mortality rate worldwide, which continues to grow as millions of people are diagnosed annually. Metastatic disease caused by cancer is largely responsible for the mortality rates, thus early detection of metastatic tumours can improve prognosis. However, a large number of patients will also present with micrometastasis tumours which are often missed, as conventional medical imaging modalities are unable to detect micrometastases due to the lack of specificity and sensitivity. Recent advances in radiochemistry and the development of nucleic acid based targeting molecules, have led to the development of novel agents for use in cancer diagnostics. Monoclonal antibodies may also be used, however, they have inherent issues, such as toxicity, cost, unspecified binding and their clinical use can be controversial. Aptamers are a class of single-stranded RNA or DNA ligands with high specificity, binding affinity and selectivity for a target, which makes them promising for molecular biomarker imaging. Aptamers are presented as being a superior choice over antibodies because of high binding affinity and pH stability, amongst other factors. A number of aptamers directed to cancer cell markers (breast, lung, colon, glioblastoma, melanoma) have been radiolabelled and characterised to date. Further work is ongoing to develop these for clinical applications.<\/jats:p>","DOI":"10.3390\/ph12010002","type":"journal-article","created":{"date-parts":[[2018,12,24]],"date-time":"2018-12-24T10:37:49Z","timestamp":1545647869000},"page":"2","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Radiolabelled Aptamers for Theranostic Treatment of Cancer"],"prefix":"10.3390","volume":"12","author":[{"given":"Umair","family":"Khalid","sequence":"first","affiliation":[{"name":"School of Medicine Deakin University, Geelong, Victoria 3128, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Vi","sequence":"additional","affiliation":[{"name":"School of Medicine Deakin University, Geelong, Victoria 3128, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Henri","sequence":"additional","affiliation":[{"name":"School of Medicine Deakin University, Geelong, Victoria 3128, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Macdonald","sequence":"additional","affiliation":[{"name":"School of Medicine Deakin University, Geelong, Victoria 3128, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Eu","sequence":"additional","affiliation":[{"name":"School of Medicine Deakin University, Geelong, Victoria 3128, Australia"},{"name":"Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Mandarano","sequence":"additional","affiliation":[{"name":"School of Medicine Deakin University, Geelong, Victoria 3128, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Shigdar","sequence":"additional","affiliation":[{"name":"School of Medicine Deakin University, Geelong, Victoria 3128, Australia"},{"name":"Centre for Molecular and Medical Research, Deakin University, Geelong, Victoria 3128, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,12,24]]},"reference":[{"key":"ref_1","unstructured":"Cooper, G. (2000). The Development and Causes of Cancer. The Cell: A Molecular Approach, Sinauer Associates. [2nd ed.]."},{"key":"ref_2","unstructured":"Martin, T., Ye, L., Sanderas, A., Lane, J., and Jiang, W. (2013). Cancer Invasion and Metastasis: Molecular and Cellular Perspective. Madame Curie Bioscience Database, Landes Bioscience."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.addr.2013.09.007","article-title":"Molecular imaging for cancer diagnosis and surgery","volume":"66","author":"Hussain","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/JCO.2007.14.3065","article-title":"New Technologies for Human Cancer Imaging","volume":"26","author":"Frangioni","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.phrs.2016.04.023","article-title":"Contrast agents in diagnostic imaging: Present and future","volume":"110","author":"Caschera","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_6","first-page":"136","article-title":"Targeted use of alpha particles: Current status in cancer therapeutics","volume":"3","author":"Sartor","year":"2012","journal-title":"J. Nucl. Med. Radiat. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4103\/0971-6203.25665","article-title":"Positron emission tomography: An overview","volume":"31","author":"Shukla","year":"2006","journal-title":"J. Med. Phys."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/B978-0-444-53485-9.00013-1","article-title":"Single-photon emission tomography","volume":"Volume 135","author":"Goffin","year":"2016","journal-title":"Handbook of Clinical Neurology"},{"key":"ref_9","first-page":"95","article-title":"Applications of PET imaging with the proliferation marker [18F]-FLT","volume":"59","author":"Peck","year":"2015","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1158\/1078-0432.CCR-16-0362","article-title":"Estrogen receptor binding (18F-FES PET) and glycolytic activity (18F-FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer","volume":"23","author":"Kurland","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ijrobp.2014.09.045","article-title":"A comparative study of the hypoxia PET tracers [18F] HX4, [18F] FAZA, and [18F] FMISO in a preclinical tumor model","volume":"91","author":"Peeters","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00259-017-3677-5","article-title":"[18F]-FMISO PET study of hypoxia in gliomas before surgery: Correlation with molecular markers of hypoxia and angiogenesis","volume":"44","author":"Bekaert","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.mayocp.2012.01.012","article-title":"Clinical Pharmacology, Uses, and Adverse Reactions of Iodinated Contrast Agents: A Primer for the Non-radiologist","volume":"87","author":"Pasternak","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1007\/s00330-003-1912-x","article-title":"Currently used non-specific extracellular MR contrast media","volume":"13","author":"Bellin","year":"2003","journal-title":"Eur. Radiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4103\/0971-3026.169467","article-title":"Emerging clinical applications of PET based molecular imaging in oncology: The promising future potential for evolving personalized cancer care","volume":"25","author":"Dhingra","year":"2015","journal-title":"Indian J. Radiol. Imaging"},{"key":"ref_16","first-page":"321","article-title":"Use of PET\/CT scanning in cancer patients: Technical and practical considerations","volume":"18","author":"Griffeth","year":"2005","journal-title":"Proc. (Bayl. Univ. Med. Cent.)"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cpet.2009.05.002","article-title":"FDG PET in Prostate Cancer","volume":"4","author":"Jadvar","year":"2009","journal-title":"PET Clin."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1740936","DOI":"10.1155\/2016\/1740936","article-title":"Cancer Stem Cell Quiescence and Plasticity as Major Challenges in Cancer Therapy","volume":"2016","author":"Chen","year":"2016","journal-title":"Stem Cells Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejca.2015.11.018","article-title":"A systematic review on [18F] FLT-PET uptake as a measure of treatment response in cancer patients","volume":"55","author":"Bollineni","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Raccagni, I., Belloli, S., Valtorta, S., Stefano, A., Presotto, L., Pascali, C., Bogni, A., Tortoreto, M., Zaffaroni, N., and Daidone, M.G. (2018). [18F] FDG and [18F] FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0197754"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.2967\/jnumed.117.193649","article-title":"Androgen and estrogen receptor imaging in metastatic breast cancer patients as a surrogate for tissue biopsies","volume":"58","author":"Venema","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2967\/jnumed.117.194654","article-title":"Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer 18F-4FMFES in Estrogen Receptor\u2013Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial","volume":"59","author":"Paquette","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_23","first-page":"1068","article-title":"18F-FES and 18F-FDG PET\/MR imaging of gynecologic tumors: Initial experience in 5 cases","volume":"58","author":"Tsujikawa","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_24","first-page":"1350","article-title":"Effects of eribulin on remodeling of tumor vasculature evaluated with 18F-FMISO hypoxia imaging in a human breast cancer cell xenograft","volume":"57","author":"Zhao","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/ph8020321","article-title":"A critical review of alpha radionuclide therapy\u2014How to deal with recoiling daughters?","volume":"8","author":"Wolterbeek","year":"2015","journal-title":"Pharmaceuticals"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3389\/fonc.2013.00324","article-title":"The potential and hurdles of targeted alpha therapy\u2013Clinical trials and beyond","volume":"3","author":"Elgqvist","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1200\/JCO.2018.36.6_suppl.344","article-title":"Clinical experience with PSMA-Actinium-225 (Ac-225) radioligand therapy (RLT) in end-stage metastatic castration-resistant prostate cancer (mCRPC) patients","volume":"36","author":"Mehra","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_28","first-page":"437","article-title":"Radiation in medicine: Origins, risks and aspirations","volume":"4","author":"Donya","year":"2014","journal-title":"Glob. Cardiol. Sci. Pract."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/10428190600572582","article-title":"Yttrium 90 ibritumomab tiuxetan in lymphoma","volume":"47","author":"Cheung","year":"2006","journal-title":"Leuk. Lymphoma"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Faderl, S., and Kantarjian, H. (2011). Leukemias: Principles and Practice of Therapy, John Wiley & Sons.","DOI":"10.1002\/9781444327359"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1479-5876-5-15","article-title":"Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: The tumor selectivity of the treatment as a function of tumor to liver flow ratio","volume":"5","author":"Gulec","year":"2007","journal-title":"J. Transl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1102\/1470-7330.2013.0057","article-title":"Yttrium-90 radioembolization of liver tumors: What do the images tell us?","volume":"13","author":"Singh","year":"2013","journal-title":"Cancer Imaging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000355821","article-title":"Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: Efficacy, safety and prognostic factors","volume":"86","author":"Michl","year":"2014","journal-title":"Oncology"},{"key":"ref_34","unstructured":"Chandra, R., and Rahmim, A. (2017). Nuclear Medicine Physics: The Basics, Lippincott Williams & Wilkins."},{"key":"ref_35","unstructured":"Hine, G.J. (2016). Instrumentation in Nuclear Medicine, Academic Press."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"968","DOI":"10.2174\/138955711797068445","article-title":"Chelating agents and their use in radiopharmaceutical sciences","volume":"11","author":"Wangler","year":"2011","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1039\/C3CS60304K","article-title":"Matching chelators to radiometals for radiopharmaceuticals","volume":"43","author":"Price","year":"2014","journal-title":"Chem. Soc. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.3390\/ma3053204","article-title":"A brief review of chelators for radiolabeling oligomers","volume":"3","author":"Liu","year":"2010","journal-title":"Materials"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.crad.2010.03.011","article-title":"Molecular imaging: Current status and emerging strategies","volume":"65","author":"Pysz","year":"2010","journal-title":"Clin. Radiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ymeth.2013.09.015","article-title":"Engineered antibodies for molecular imaging of cancer","volume":"65","author":"Wu","year":"2014","journal-title":"Methods (San Diego Calif.)"},{"key":"ref_41","first-page":"14","article-title":"Monoclonal antibodies in cancer therapy","volume":"12","author":"Scott","year":"2012","journal-title":"Cancer Immun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.molonc.2014.03.010","article-title":"Theranostic applications of antibodies in oncology","volume":"8","author":"Fleuren","year":"2014","journal-title":"Mol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s10555-014-9505-5","article-title":"Antibody-based imaging strategies for cancer","volume":"33","author":"Warram","year":"2014","journal-title":"Cancer Metastasis Rev."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"R\u00f6thlisberger, P., Gasse, C., and Hollenstein, M. (2017). Nucleic Acid Aptamers: Emerging Applications in Medical Imaging, Nanotechnology, Neurosciences, and Drug Delivery. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18112430"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.apradiso.2013.01.039","article-title":"Clinical applications of Gallium-68","volume":"76","author":"Banerjee","year":"2013","journal-title":"Appl. Radiat. Isot."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e6525","DOI":"10.1073\/pnas.1502648112","article-title":"Targeting CD146 with a 64Cu-labeled antibody enables in vivo immunoPET imaging of high-grade gliomas","volume":"112","author":"Yang","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2147\/IJN.S62837","article-title":"Bio-functionalized dense-silica nanoparticles for MR\/NIRF imaging of CD146 in gastric cancer","volume":"10","author":"Wang","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1007\/s00259-016-3442-1","article-title":"ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer","volume":"43","author":"Sun","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"10919","DOI":"10.18632\/oncotarget.14229","article-title":"Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging","volume":"8","author":"Frigerio","year":"2017","journal-title":"Oncotarget"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1148\/rg.2016150059","article-title":"Molecular imaging of prostate cancer","volume":"36","author":"Wibmer","year":"2015","journal-title":"Radiographics"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13550-015-0104-4","article-title":"Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors","volume":"5","author":"Divgi","year":"2015","journal-title":"EJNMMI Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients","volume":"58","author":"Rahbar","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2967\/jnumed.117.193888","article-title":"Tumor uptake of 64Cu-DOTA-trastuzumab in patients with metastatic breast cancer","volume":"59","author":"Mortimer","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_54","first-page":"23","article-title":"Functional imaging of HER2-positive metastatic breast cancer using 64Cu-DOTA-trastuzumab positron emission tomography","volume":"55","author":"Mortimer","year":"2014","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s11307-016-0951-z","article-title":"[89 Zr] Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer","volume":"18","author":"Laforest","year":"2016","journal-title":"Mol. Imaging Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.2967\/jnumed.115.172031","article-title":"Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using 89Zr-trastuzumab PET\/CT","volume":"57","author":"Ulaner","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fphar.2016.00131","article-title":"Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology: What can we learn from initial clinical trials?","volume":"7","author":"Jauw","year":"2016","journal-title":"Front. Pharmacol."},{"key":"ref_58","first-page":"155","article-title":"Affinity and avidity in antibody-based tumor targeting","volume":"24","author":"Rudnick","year":"2009","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"6406","DOI":"10.1158\/1078-0432.CCR-11-0483","article-title":"Antibody-radionuclide conjugates for cancer therapy: Historical considerations and new trends","volume":"17","author":"Steiner","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_60","first-page":"878","article-title":"Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates","volume":"55","author":"Kukis","year":"1995","journal-title":"Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/B978-0-7020-4087-0.00076-0","article-title":"Commonly used drugs in hematologic disorders","volume":"Volume 120","author":"Anderes","year":"2014","journal-title":"Handbook of Clinical Neurology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"708","DOI":"10.7150\/thno.8156","article-title":"Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody","volume":"4","author":"Vincke","year":"2014","journal-title":"Theranostics"},{"key":"ref_63","first-page":"57","article-title":"A Radiolabeled Fully Human Antibody to Human Aspartyl (Asparaginyl) \u03b2-Hydroxylase Is a Promising Agent for Imaging and Therapy of Metastatic Breast Cancer","volume":"32","author":"Revskaya","year":"2017","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_64","first-page":"441","article-title":"Synthesis and stability test of radioimmunoconjugate 177Lu-DOTA-F (ab\u2032) 2-trastuzumab for theranostic agent of HER2 positive breast cancer","volume":"9","author":"Hermanto","year":"2016","journal-title":"J. Radiat. Res. Appl. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1053\/j.seminoncol.2014.07.004","article-title":"Radioimmunoconjugates for the Treatment of Cancer","volume":"41","author":"Rousseau","year":"2014","journal-title":"Semin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1053\/j.semnuclmed.2009.12.005","article-title":"Antibody Vectors for Imaging","volume":"40","author":"Olafsen","year":"2010","journal-title":"Semin. Nucl. Med."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Collin de l\u2019Hortet, A., Gilgenkrantz, H., and Guidotti, J.-E. (2012). EGFR: A master piece in G1\/S phase transition of liver regeneration. Int. J. Hepatol., 2012.","DOI":"10.1155\/2012\/476910"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2967\/jnumed.108.055525","article-title":"Affibody molecules for epidermal growth factor receptor targeting in vivo: Aspects of dimerization and labeling chemistry","volume":"50","author":"Tolmachev","year":"2009","journal-title":"J. Nucl. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: Current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2967\/jnumed.110.075101","article-title":"Renal toxicity of radiolabeled peptides and antibody fragments: Mechanisms, impact on radionuclide therapy, and strategies for prevention","volume":"51","author":"Vegt","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Thundimadathil, J. (2012). Cancer treatment using peptides: Current therapies and future prospects. J. Amino Acids, 2012.","DOI":"10.1155\/2012\/967347"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Rufini, V., Calcagni, M.L., and Baum, R.P. (2006). Imaging of Neuroendocrine Tumors, Elsevier.","DOI":"10.1053\/j.semnuclmed.2006.03.007"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.2174\/1381612023393756","article-title":"Experience with indium-111 and yttrium-90-labeled somatostatin analogs","volume":"8","author":"Virgolini","year":"2002","journal-title":"Curr. Pharm. Des."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/01.mnm.0000126628.01919.f9","article-title":"99mTc-depreotide tumour uptake in patients with non-Hodgkin\u2019s lymphoma","volume":"25","author":"Bushnell","year":"2004","journal-title":"Nucl. Med. Commun."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1007\/s00259-006-0172-9","article-title":"Comparison of [177 Lu-DOTA 0, Tyr 3] octreotate and [177 Lu-DOTA 0, Tyr 3] octreotide: Which peptide is preferable for PRRT?","volume":"33","author":"Esser","year":"2006","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1053\/j.semnuclmed.2017.05.007","article-title":"Clinical Applications of Radiolabeled Peptides for PET","volume":"47","author":"Jackson","year":"2017","journal-title":"Semin. Nucl. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"618","DOI":"10.7150\/thno.11251","article-title":"Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging","volume":"5","author":"Wester","year":"2015","journal-title":"Theranostics"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2174\/187152109789760216","article-title":"Peptidomimetics and their Applications in Antifungal Drug Design","volume":"8","author":"Shoeib","year":"2009","journal-title":"Anti-Infect. Agents Med. Chem."},{"key":"ref_79","first-page":"885","article-title":"Pharmacologic characterization of CHIR 2279, an N-substituted glycine peptoid with high-affinity binding for alpha 1-adrenoceptors","volume":"277","author":"Gibbons","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_80","first-page":"152","article-title":"First-in-human study demonstrating tumor-angiogenesis by PET\/CT imaging with 68Ga-NODAGA-THERANOST, a high-affinity peptidomimetic for \u03b1v\u03b23 integrin receptor targeting","volume":"30","author":"Baum","year":"2015","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_81","unstructured":"U.S. National Library of Medicine (2018, November 30). PET\/CT Imaging of Angiogenesis in Patients with Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03271281?term=nodaga&rank=4."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","article-title":"The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer","volume":"42","author":"Avtzi","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Giesel, F.L., Knorr, K., Spohn, F., Will, L., Maurer, T., Flechsig, P., Neels, O., Schiller, K., Amaral, H., and Weber, W. (2018). Detection efficacy of [18F]PSMA-1007 PET\/CT in 251 Patients with biochemical recurrence after radical prostatectomy. J. Nucl. Med.","DOI":"10.2967\/jnumed.118.212233"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2967\/jnumed.117.194209","article-title":"Repeated 177Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq","volume":"59","author":"Rathke","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2967\/jnumed.118.209387","article-title":"Potential Impact of 68Ga-PSMA-11 PET\/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer","volume":"59","author":"Calais","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"De Visschere, P.J.L., Standaert, C., F\u00fctterer, J.J., Villeirs, G.M., Panebianco, V., Walz, J., Maurer, T., Hadaschik, B.A., Lecouvet, F.E., and Giannarini, G. (2018). A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer. Eur. Urol. Oncol.","DOI":"10.1016\/j.euo.2018.09.010"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): A single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1021\/ac102845y","article-title":"Evaluation of androgenic activity of nutraceutical-derived steroids using mammalian and yeast in vitro androgen bioassays","volume":"83","author":"Akram","year":"2011","journal-title":"Anal. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1677\/erc.0.0110117","article-title":"Mechanisms of androgen receptor signalling via steroid receptor coactivator-1 in prostate","volume":"11","author":"Powell","year":"2004","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1158\/1541-7786.MCR-13-0611","article-title":"Tailoring peptidomimetics for targeting protein\u2013protein interactions","volume":"12","author":"Akram","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fchem.2014.00062","article-title":"Current challenges in peptide-based drug discovery","volume":"2","author":"Otvos","year":"2014","journal-title":"Front. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/j.1349-7006.2011.01897.x","article-title":"RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule","volume":"102","author":"Shigdar","year":"2011","journal-title":"Cancer Sci."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"34","DOI":"10.32607\/20758251-2013-5-4-34-43","article-title":"Aptamers: Problems, solutions and prospects","volume":"5","author":"Lakhin","year":"2013","journal-title":"Acta Nat."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Hays, E.M., Duan, W., and Shigdar, S. (2017). Aptamers and Glioblastoma: Their Potential Use for Imaging and Therapeutic Applications. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18122576"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.2200121","article-title":"Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase","volume":"249","author":"Tuerk","year":"1990","journal-title":"Science"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"13624","DOI":"10.3390\/s131013624","article-title":"Aptamers as theranostic agents: Modifications, serum stability and functionalisation","volume":"13","author":"Shigdar","year":"2013","journal-title":"Sensors"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/346818a0","article-title":"In vitro selection of RNA molecules that bind specific ligands","volume":"346","author":"Ellington","year":"1990","journal-title":"Nature"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.nucmedbio.2015.09.005","article-title":"Aptamers as radiopharmaceuticals for nuclear imaging and therapy","volume":"43","author":"Gijs","year":"2016","journal-title":"Nucl. Med. Biol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2967\/jnumed.113.126144","article-title":"Current Progress of Aptamer-Based Molecular Imaging","volume":"55","author":"Wang","year":"2014","journal-title":"J. Nucl. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"234","DOI":"10.5483\/BMBRep.2015.48.4.277","article-title":"Therapeutic aptamers: Developmental potential as anticancer drugs","volume":"48","author":"Lee","year":"2015","journal-title":"BMB Rep."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.7150\/thno.11711","article-title":"Superior Performance of Aptamer in Tumor Penetration over Antibody: Implication of Aptamer-Based Theranostics in Solid Tumors","volume":"5","author":"Xiang","year":"2015","journal-title":"Theranostics"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Macdonald, J., Henri, J., Roy, K., Hays, E., Bauer, M., Veedu, R.N., Pouliot, N., and Shigdar, S. (2018). EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs. Cancers, 10.","DOI":"10.3390\/cancers10010019"},{"key":"ref_103","first-page":"668","article-title":"Tumor targeting by an aptamer","volume":"47","author":"Hicke","year":"2006","journal-title":"J. Nucl. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.nucmedbio.2009.04.004","article-title":"Anti-MUC1 aptamers: Radiolabelling with 99mTc and biodistribution in MCF-7 tumour-bearing mice","volume":"36","author":"Perkins","year":"2009","journal-title":"Nucl. Med. Biol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Kryza, D., Debordeaux, F., Az\u00e9ma, L., Hassan, A., Paurelle, O., Schulz, J., Savona-Baron, C., Charignon, E., Bonazza, P., and Taleb, J. (2016). Ex vivo and in vivo imaging and biodistribution of aptamers targeting the human matrix metalloprotease-9 in melanomas. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0149387"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Yoon, S., and Rossi, J. (2018). Targeted molecular imaging using aptamers in cancer. Pharmaceuticals, 11.","DOI":"10.3390\/ph11030071"},{"key":"ref_107","first-page":"1915","article-title":"Evaluation of 64Cu-DOTA-AS1411 as a PET tracer for lung cancer imaging","volume":"50","author":"Li","year":"2009","journal-title":"J. Nucl. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.nucmedbio.2013.10.008","article-title":"Aptamer imaging with Cu-64 labeled AS1411: Preliminary assessment in lung cancer","volume":"41","author":"Li","year":"2014","journal-title":"Nucl. Med. Biol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1021\/acs.bioconjchem.6b00746","article-title":"Combinatorial screening of DNA aptamers for molecular imaging of HER2 in cancer","volume":"28","author":"Zhu","year":"2017","journal-title":"Bioconj. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/jmrs.227","article-title":"Lutetium (177) PSMA radionuclide therapy for men with prostate cancer: A review of the current literature and discussion of practical aspects of therapy","volume":"64","author":"Emmett","year":"2017","journal-title":"J. Med. Radiat. Sci."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2353\/ajpath.2007.070152","article-title":"Epithelial cell adhesion molecule: More than a carcinoma marker and adhesion molecule","volume":"171","author":"Trzpis","year":"2007","journal-title":"Am. J. Pathol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ncb1824","article-title":"Nuclear signalling by tumour-associated antigen EpCAM","volume":"11","author":"Maetzel","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1093\/carcin\/bgq187","article-title":"EpCAM in carcinogenesis: The good, the bad or the ugly","volume":"31","author":"Melchers","year":"2010","journal-title":"Carcinogenesis"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/annonc\/mdp314","article-title":"An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer","volume":"21","author":"Schmidt","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/bjc.2013.80","article-title":"EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2(+), basal-like, and HER2 intrinsic subtypes of breast cancer","volume":"108","author":"Soysal","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Suzuki, Y., Iida, M., Miura, I., Inubushi, T., and Morikawa, S. (2014). A Polymer-Based Magnetic Resonance Tracer for Visualization of Solid Tumors by 13C Spectroscopic Imaging. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0102132"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Alshaer, W., Ababneh, N., Hatmal, M., Izmirli, H., Choukeife, M., Shraim, A., Sharar, N., Abu-Shiekah, A., Odeh, F., and Al Bawab, A. (2017). Selection and targeting of EpCAM protein by ssDNA aptamer. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0189558"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1021\/ac400366b","article-title":"Selection of DNA Aptamers against Epithelial Cell Adhesion Molecule for Cancer Cell Imaging and Circulating Tumor Cell Capture","volume":"85","author":"Song","year":"2013","journal-title":"Anal. Chem."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1021\/acschemneuro.6b00369","article-title":"Development of a Bifunctional Aptamer Targeting the Transferrin Receptor and Epithelial Cell Adhesion Molecule (EpCAM) for the Treatment of Brain Cancer Metastases","volume":"8","author":"Macdonald","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1177\/0284185116681041","article-title":"Diagnostic impact of integrated 18F-FDG PET\/MRI in cerebral staging of patients with non-small cell lung cancer","volume":"58","author":"Deuschl","year":"2017","journal-title":"Acta Radiol."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Ni, S., Yao, H., Wang, L., Lu, J., Jiang, F., Lu, A., and Zhang, G. (2017). Chemical Modifications of Nucleic Acid Aptamers for Therapeutic Purposes. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18081683"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.2174\/092986711797189600","article-title":"Nucleic acid aptamers: Clinical applications and promising new horizons","volume":"18","author":"Ni","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"423","DOI":"10.4062\/biomolther.2013.085","article-title":"Nucleic Acid Aptamers: New Methods for Selection, Stabilization, and Application in Biomedical Science","volume":"21","author":"Kong","year":"2013","journal-title":"Biomol. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: Current potential and challenges","volume":"16","author":"Zhou","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1517\/17425247.2015.993313","article-title":"Albumin and its application in drug delivery","volume":"12","author":"Sleep","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40591-016-0048-8","article-title":"Albumin-based drug delivery: Harnessing nature to cure disease","volume":"4","author":"Larsen","year":"2016","journal-title":"Mol. Cell. Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1210\/me.2014-1230","article-title":"Editorial: Antibody Can Get It Right: Confronting Problems of Antibody Specificity and Irreproducibility","volume":"28","author":"Schonbrunn","year":"2014","journal-title":"Mol. Endocrinol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/521274a","article-title":"Reproducibility crisis: Blame it on the antibodies","volume":"521","author":"Baker","year":"2015","journal-title":"Nat. News"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jconrel.2010.06.025","article-title":"Fibrin glue as a drug delivery system","volume":"148","author":"Spicer","year":"2010","journal-title":"J. Control. Release"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"52553","DOI":"10.18632\/oncotarget.9651","article-title":"Targeting folate receptor alpha for cancer treatment","volume":"7","author":"Cheung","year":"2016","journal-title":"Oncotarget"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1080\/10717544.2018.1450910","article-title":"Application of hyaluronic acid as carriers in drug delivery","volume":"25","author":"Huang","year":"2018","journal-title":"Drug Deliv."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"153","DOI":"10.23736\/S1824-4785.17.02971-5","article-title":"Radiolabeled peptides: Current and new perspectives","volume":"61","author":"Opalinska","year":"2017","journal-title":"Q. J. Nucl. Med. Mol. Imaging"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/12\/1\/2\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:35:55Z","timestamp":1760196955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/12\/1\/2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,24]]},"references-count":132,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,3]]}},"alternative-id":["ph12010002"],"URL":"https:\/\/doi.org\/10.3390\/ph12010002","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,24]]}}}